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Abstract
Objective: Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available 
in Japan. In a hemodialysis patient with cecal cancer, we investigated the efﬁ  cacy, safety, pharmacokinetics, and dialysability 
of oxaliplatin.
Methods: A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m
2) and l-leucovorin(l-LV) (200 
mg/m
2), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 
5-FU (400 mg/m
2) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m
2) over 46 hours via the main 
tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. 
Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum 
clearance.
Results: The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell 
from 0.32 µg/mL to 0.15 µg/mL.
Conclusion: Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it 
is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term 
treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal 
cancer.
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Mini-abstract
The efﬁ  cacy, safety, pharmacokinetics, and dialysability of oxaliplatin were assessed in a hemodialysis patient with recurrent 
cecal cancer.
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Introduction
Oxaliplatin (L-OHP) is a key component of the standard regimen for colorectal cancer in Western 
countries and it has recently become available in Japan. L-OHP has unique characteristics compared 
with other platinum compounds; it possesses a 1,2-diaminocyclohexane group and a labile oxalate 
ligand leaving group. This drug has proved effective for colorectal cancer that is unresponsive to other 
platinum compounds 
1.
L-OHP is excreted very slowly in the urine because it shows irreversible protein binding 
2. In other 
countries, this drug has been used to treat patients with renal dysfunction 
3,4, but not hemodialysis 
patients with renal failure. We administered L-OHP to a hemodialysis patient with cecal cancer, and 
investigated its efﬁ  cacy, safety, pharmacokinetics, and dialysability.98
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Case Report
The patient was a 65-year-old man with a history of 
diabetes mellitus since the age of 46 years and 
hypertension since the age of 61. He had been on 
hemodialysis due to diabetic nephropathy for 4 
years.
In February 2004, cecal cancer with liver 
metastases and peritoneal dissemination was diag-
nosed, and he underwent ileocecal resection plus 
microwave coagulation therapy for the hepatic 
metastases. Postoperatively, S-I (a novel oral 
compound of tegafur, gimestat, and otastat potas-
sium at a ratio of 1:0.4:1 that is aimed at the bio-
chemical modulation of 5-fluorouracil, was 
administered at a dose of 40 mg. Since peritoneal 
dissemination was progressive, irinotecan hydro-
chloride was then administered at a dose of 80 mg 
every two weeks from February 2005. In May 
2005, tumor dissemination showed progression, 
and tumor marker levels also increased. Abdomi-
nal CT scanning revealed ascites and disseminated 
peritoneal metastases (Fig. 1). Therefore, he was 
hospitalized for treatment.
On admission, the patient was 165.5 cm tall and 
weighed 53.0 kg. His conjunctivae were slightly 
pale. An abdominal tumor was palpable to the right 
of the umbilicus and intestinal peristalsis was 
slightly increased.
The laboratory ﬁ  ndings on admission were as 
follows: a white blood cell count of 5.3 × 10
3/µL, 
hemoglobin of 8.9 g/dL, platelet count of 18.6 × 10
4, 
total protein of 5.8 g/dL, AST of 10 IU/L, ALT of 
2 IU/L, T-Bil of 0.38 mg/dL, urea nitrogen of 29.2 
mg/dL, creatinine of 6.49 mg/dL, CEA of 27.8 ng/
mL, and CA19-9 of 633.0 U/mL.
The patient was treated with reference to the 
modified FOLFOX6 protocol (mFOLFOX6).10 
L-OHP (40 mg/m
2 for a total dose of 63 mg) and 
1-LV (200 mg/m
2: a total dose of 314 mg) were 
administered simultaneously over 120 min via the 
side and the main tubes of a Y-tube, respectively. 
Then 5-ﬂ  uorouraci (5-FU) (400 mg/m
2: a total dose 
of 628 mg) was administered rapidly via the side 
tube, followed by 5-FU (2,000 mg/m
2: a total 
dose of 3,140 mg) via the main tube over 46 hours. 
The dose of L-OHP was set at 40 mg/m,
2 because 
its area under the concentration vs. time curve (AUC) 
was reported to increase two-fold when the creatinine 
clearance was 60 mL/min or less 
3. Hemodialysis 
was performed 3 times a week (Monday, Wednesday, 
and Friday), and was started 30 min after completing 
the administration of L-OHP. The free platinum level 
in plasma ultraﬁ  ltrate was measured immediately 
after the administration of L-OHP, at 15 min after-
ward, before hemodialysis, immediately after start-
ing hemodialysis, at 30, 60, 90, 120, 150, and 180 
min after starting hemodialysis, and after the comple-
tion of hemodialysis. To measure the platinum level 
after administration of L-OHP, blood samples were 
collected from the dialyzer before and after each 
hemodialysis session to examine platinum clearance 
by hemodialysis. Each blood sample was centrifuged 
immediately after collection, and 1 mL of plasma 
was subjected to ultraﬁ  ltration using an Amicon
® 
ﬁ  lter with a molecular cut-off of 30,000 Da. Then 
assay of platinum was performed as reported by 
Gilmour et al. 
5.
Hemodialysis was performed for 3 hours at a 
blood ﬂ  ow rate of 200 mL/min using a TR-2001N 
dialysis membrane and a BG-1.8U dialyzer (Toray 
Figure 1. CT scans of a 65-year-old patient with peritoneal dis-
semination prior to L-OHP administration. (a) Nodular masses can 
be seen in the peritoneal cavity. (b) Ascites can be seen around the 
spleen.
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Medical Co., Ltd., Tokyo, Japan). Informed 
consent was obtained from the patient for the 
administration of L-OHP and measurement of 
blood drug levels. Adverse reactions were classi-
ﬁ  ed according to Commom Terminology Criteria 
for Adverse Events version 3.0 
15.
To avoid accumulation of L-OHP, it was sched-
uled to be administered at 3–week intervals. 
Administration was done on schedule during the 
second course, but the third course was delayed 
by 1 week. As adverse events, the neuropathy did 
not appear in all courses.(Grade 0) and anorexia 
(Grade 2) and fatigue (Grade 2) developed at 
1 week after administration of L-OHP during the 
ﬁ  rst course of therapy. During the second course, 
anorexia (Grade 3), constipation (Grade 2), and 
fatigue (Grade 3) occurred, leading to delay of the 
third course. There was no tumor regression 
(Fig. 3). On September 26, the patient died due to 
progression of his cancer.
Results
Figure 2 shows the platinum level in plasma ultra-
filtrate after administration of L-OHP. During 
hemodialysis, the platinum level decreased from 
0.32 µg/mL at baseline to 0.24, 0.2, 0.16, and 
0.14 µg/mL, showing a decline of about 50%. The 
removal rate of platinum by the dialyzer was 80% 
irrespective of the time after starting hemodialysis.
Discussion
The number of patients on hemodialysis due to 
renal failure has been increasing steadily in Japan. 
In 2000, there were 206,134 such patients, and 
18,938 of them died of malignant diseases. Since 
malignancy ranks fourth among the causes of death 
for hemodialysis patients, treatment of cancer in 
these patients is a major problem 
6.
At present, there are no established chemo-
therapy for the treatment of malignant diseases 
having hemodialysis. In 1998, the total number of 
cancer deaths was 284,000, and colorectal cancer 
accounted for 12.1%, ranking third after lung can-
cer and gastric cancer 
7–10.
For these reasons, effective chemotherapy for 
colorectal cancer in hemodialysis patients is needed.
In Western countries, combination chemother-
apy with 5-FU, 1-LV, and L-OHP (FOLFOX) 
is commonly used as first-line treatment for 
colorectal cancer 
11. L-OHP has also been approved 
in Japan recently, so that 5-FU, 1-LV, L-OHP, and 
irinotecan (used in Western countries as standard 
chemotherapy for colorectal cancer) can now be 
used in Japan.
We administered reduced-dose mFOLFOX6 to 
our hemodialysis patient with cecal cancer that was 
refractory to S-1 and irinotecan, and measured the 
platinum level over time. L-OHP is a third-
generation platinum derivative that is eliminated 
Figure 2. Effect of hemodialysis on platinum concentration in plasma ultraﬁ  ltrate.
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via the kidneys. According to pharmacokinetic 
studies, the protein-binding rate of L-OHP is 
85%–88%, which is similar to that of other plati-
num compounds. However, L-OHP shows irrevers-
ible binding to erythrocytes and thus is slowly 
eliminated from the body, with the t1/2 for elimina-
tion from erythrocytes being 400–600 hours 
2. 
Also, the plasma t1/2 for platinum was reported 
to be as long as 392 hours in men without liver 
metastasis who were under 65 years old. These 
ﬁ  ndings suggest that, unlike other platinum prepa-
rations, Reanal function has little inﬂ  uence on L-
OHP toxicities and the long terminal half lives are 
likely due to inactive species of L-OHP as exata-
polated from the absence of increased toxicity in 
spite of such ultraﬁ  lterable platinum retention. 
Comparison between patients classiﬁ  ed into groups 
on the basis of a creatinine clearance (Ccr) of 
60 mL/min, has revealed signiﬁ  cant differences in 
the total dose of L-OHP and the t1/2 (β), while there 
was no difference of adverse events 
4. A group of 
investigators at the NCI (U.S.A) also administered 
this drug to patients with a Ccr of 20 mL/min. They 
found no inﬂ  uence on the development of adverse 
events, although the AUC was elevated, but the 
number of subjects was small 
12.
It has been reported that the standard dose of 
5-FU can be administered to hemodialysis patients, 
because 80% or more of this drug is metabolized 
and inactivated in the liver, most of the metabolites 
are eliminated in the expired air, the protein-binding 
rate is low, and it is dialyzable 
13. However, it was 
also reported that blood drug levels were higher than 
those observed in healthy volunteers when 5-FU 
was administered orally to patients with renal failure 
or was given by rapid intravenous injection 
14.
Although 5-FU levels were not examined in our 
patient, the platinum level (released from L-OHP) 
was 0.42, 0.29, and 0.32 µg/mL immediately after 
administration, at 15 min after the administration, 
and just before hemodialysis, respectively. The 
platinum level before the dialyzer circuit was 
0.11–0.32 µg/mL. A pharmacokinetic study of L-
OHP performed in Japanese subjects showed that 
the blood level of platinum around 0.2 µg/mL for 
24 hours from 3 hours after administration. These 
results suggest that the blood platinum level may 
have a similar proﬁ  le to that in patients who are 
not on dialysis, although no deﬁ  nite conclusions 
can be drawn because we have only examined 
pharmacokinetic parameters in one patient. 
Although the dose of L-OHP was reduced to 
40 mg/m
2, the AUC was increased in agreement 
with previous reports on patients who had impaired 
renal function. The platinum level after the dialyzer 
circuit was 0.02–0.07 µg/mL, which suggests the 
possibility of L-OHP being dialysable. Considering 
that the t1/2γ of L-OHP was 392 hours, that the 
24-hour urinary excretion rate after its administra-
tion at 130 mg/m
2 was 33.9 ± 8.8% of the total 
platinum dose in the Japanese phase I study, and 
that the 120-hour urinary excretion rate was 
reported to be 53.8 ± 9.1% overseas, this drug is 
considered to be tolerable for patients on hemodi-
alysis 3 times a week.
It was difficult to evaluate adverse events 
because our patient had advanced cancer. However, 
gastrointestinal symptoms appeared to be slight, 
but persistent. Although their relationship to renal 
failure could not be properly evaluated, considering 
the possible accumulation of L-OHP, it may be 
Figure 3. CT scans obtained after L-OHP administration. (a) The 
nodular masses are larger than before. (b) Ascites has increased 
around the spleen.
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more appropriate to administer this drug at intervals 
of at least 3 weeks. Since patients with renal failure 
have various associated disorders and the blood 
half-life of L-OHP is long, it will be necessary to 
collect more pharmacokinetic data to investigate 
its accumulation and dialysability in patients 
receiving this drug over the long term. Such data 
will assist in treating the rapidly increasing number 
of hemodialysis patients with colorectal cancer.
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